leisure time -WSS

leisure time

author：leisure time 2025-09-29 21:13:58 - browse：37246

Ula Jurkunas, associate director of the cornea service at Mass Eye and Ear, performs the first CALEC surgery. Courtesy Mass Eye and Ear

The first time Phillip Durst saw the big A on the chart, he could hardly believe it. It was the first in a series of letters to check his vision in his left eye. “They keep flipping the chart and it keeps getting smaller and smaller, and I keep identifying the letters — that was huge,” said Durst. “It’s like a miracle.”

A year earlier, in April 2017, Durst had lost sight from that same eye after it was hit by a caustic water treatment solution in a work accident. The damage was so severe that a standard corneal transplant would not resolve it. But in April 2018, he underwent a new, innovative procedure: An eye stem cell transplant led by Ula Jurkunas, the associate director of the cornea service at Mass Eye and Ear in Boston.

Durst, now 51 years old, is the first of four patients who were included in a Phase 1 trial of Cultivated Autologous Limbal Epithelial Cell (CALEC) transplant, the results of which were published Friday in Science Advances. The procedure allowed him to become a suitable candidate for another surgery, the artificial corneal transplant, while rehabilitating his vision — and his life.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Can CDC director Mandy Cohen drive consensus in Washington?

WSS

Argenx drug significantly slows progression of nerve disorder

Georgia court denies Trump's request to quash DA's 2020 election probe

Woman gored by Bison at Yellowstone

Congress: Eradicate hepatitis C and reduce the deficit

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Shifting the focus from loneliness to social health

Wikipedia

leisure time

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

Walensky prepares to leave CDC — and Congress — behind

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How to increase colonoscopy rates? Looks like an AI can help

Continuity nursing helped my family in our darkest PICU moments

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Hollywood unions extend contract negotiations for actors

NIH documents show early flaws of $1.6 billion long Covid program

focus

BMI, flaws aside, is found to be useful estimate of body fat in youth

Care demand spikes challenge UnitedHealth’s provider arm

Why police arrested suspected Gilgo Beach killer away from his house

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Involuntary treatment for addiction doesn't work

Grail faces three suits alleging harassment, retaliation

knowledge

hotspot

focus

hotspot